Effect of Sitagliptin on Micro150-5p in patients with T2DM with left ventricular diastolic dysfunction.

Objective: Aim: To clarify Sitagliptin effect on left ventricular diastolic dysfunction in T2DM, to investigate the potential effect of Sitagliptin on epigenetic modulation (Micro RNA150-5P) and inflammatory process.

Patients and methods: Materials and Methods: This study was carried out at a single center and is cross-sectional, descriptive, and observational. A specialist cardiologist selected a cohort of sixty individuals who had both left ventricular diastolic failure and type 2 diabetes mellitus (T2DM). The study was carried out at AL-Diwaniyah teaching hospital and the department of pharmacology and therapeutics, school of medicine, university of Al-Qadisiyah, Iraq. Total RNA was isolated using Trizol reagent (Genaid, Korea) and the concentration of RNA was determined. The primer amplification was performed according to the instructions published by AddBio (Korea) for the AddScript RT-qPCR Syber master kit. Transthoracic echocardiography measuring were patients at rest utilizing a commercially accessible ultrasound machine (Vinno E20; Echo Ultrasound AS, china). Ultrasound imaging acquisitions were automatically saved from at least three following cardiac contractions for subsequent processing. Standard parameters (LVED, LVES, and LVEF) were acquired as previously explained.

Results: Results: Our results indicate a significant down regulation of miR-150-5p in the Sitagliptin treated group (P<0.0001) in comparison with metformin treatment. This was analyzed by Graph pad prizim software (version 8.4.3).

Conclusion: Conclusions: The results of our study indicate that the expression of miR-150-5p is dramatically reduced in the cardiac tissue of individuals with diabetes. Furthermore, reducing the levels of miR-150-5p is linked to an enhancement in the functioning of the left ventricle, partially via reducing the occurrence of programmed cell death in heart muscle cells. Hence, suppressing the activity of miR-150-5p could be a new and effective approach for treating cardiac dysfunction associated with diabetes.